Godmorgen

]]>https://dev.proinvestor.com/forum/topic/399184/genmab-maj-2024RSS for NodeSun, 07 Jun 2026 20:28:42 GMTWed, 01 May 2024 02:05:49 GMT60Today, the robust clinical development of Amivantamab for EGFR-mutant NSCLC adds a new chapter looking towards a stronger future.
Soon, the Paloma-3 study will be discussed by Natasha Leighl.
Honored to have been part of this significant milestone https://x.com/apassaromd/status/1796614821670015322?s=61&t=Ry4q9LC1jDgQzC__0QIEPg

]]>https://dev.proinvestor.com/forum/post/7675430https://dev.proinvestor.com/forum/post/7675430Fri, 31 May 2024 17:24:11 GMTyeah, i was joking. it is amazing what they produce though
sometimes...

]]>https://dev.proinvestor.com/forum/post/7675431https://dev.proinvestor.com/forum/post/7675431Fri, 31 May 2024 14:04:59 GMTHa EL, ville det ikke være dejligt hvis den kunne det Det kan den desværre ikke svare på, men den kan bruges til at analysere tekster og komme med kvalificerede bud på baseret på hvad du har fodre den med.

]]>https://dev.proinvestor.com/forum/post/7675432https://dev.proinvestor.com/forum/post/7675432Fri, 31 May 2024 13:38:06 GMTAdditionally, analysts “would be keen to see detail on the tolerability, particularly the avoidance of bleeding events, which had been a concern in previous studies evaluating tisotumab vedotin in head and neck cancer,” according to the report.'

]]>https://dev.proinvestor.com/forum/post/7675428https://dev.proinvestor.com/forum/post/7675428Fri, 31 May 2024 13:25:18 GMT'On June 3, researchers will be presenting Phase II data on Pfizer and Genmab’s Tivdak (tisotumab vedotin) in head and neck squamous cell carcinoma. Analysts from Leerink Partners were encouraged by the data, positing that they “could see antibody drug-conjugates (ADCs) eventually replace chemotherapy in [the] head and neck cancer treatment paradigm, particularly in the second line space,” according to a report.

]]>https://dev.proinvestor.com/forum/post/7675425https://dev.proinvestor.com/forum/post/7675425Fri, 31 May 2024 13:25:09 GMTASCO24 Preview: A Look at Some of the Cancer Meeting’s Hottest Abstracts https://www.biospace.com/article/asco-2024-preview-a-look-at-some-of-the-cancer-meeting-s-hottest-abstracts

]]>https://dev.proinvestor.com/forum/post/7675426https://dev.proinvestor.com/forum/post/7675426Fri, 31 May 2024 13:24:59 GMTJeg kan varmt anbefale, at enhver udtalelse fra nohope tages med et gran salt. Men det ved vi jo.

]]>https://dev.proinvestor.com/forum/post/7675422https://dev.proinvestor.com/forum/post/7675422Fri, 31 May 2024 13:24:15 GMTtalking about arbitration; we haven't seen volume like this in years; last time bigger was september 2020 when the arbitration started...

]]>https://dev.proinvestor.com/forum/post/7675424https://dev.proinvestor.com/forum/post/7675424Fri, 31 May 2024 13:16:20 GMTi don't know what to believe anymore... at least now they know how to do an arbitration correct this time around...

]]>https://dev.proinvestor.com/forum/post/7675419https://dev.proinvestor.com/forum/post/7675419Fri, 31 May 2024 13:09:57 GMTno its only month end, not Q end yet

]]>https://dev.proinvestor.com/forum/post/7675420https://dev.proinvestor.com/forum/post/7675420Fri, 31 May 2024 13:08:28 GMTYes - but do we believe that. Jan said the same about sc dara in the b
eginning

]]>https://dev.proinvestor.com/forum/post/7675427https://dev.proinvestor.com/forum/post/7675427Fri, 31 May 2024 13:08:23 GMTlast day.crazy volume

]]>https://dev.proinvestor.com/forum/post/7675421https://dev.proinvestor.com/forum/post/7675421Fri, 31 May 2024 13:07:45 GMTend of the q2 EL

]]>https://dev.proinvestor.com/forum/post/7675423https://dev.proinvestor.com/forum/post/7675423Fri, 31 May 2024 13:07:20 GMTno i am not sure about that, i think once there was a question on the Q&A on this if i am not mistaken after Dara and Genmab answered something like 'all other contracts are fine'? anyone remember?

]]>https://dev.proinvestor.com/forum/post/7675418https://dev.proinvestor.com/forum/post/7675418Fri, 31 May 2024 13:06:17 GMTwtf I see Volume
704,391shares on Yahoo, is that correct

]]>https://dev.proinvestor.com/forum/post/7675417https://dev.proinvestor.com/forum/post/7675417Fri, 31 May 2024 13:04:43 GMTDo we know for sure if Genmab gets the same royalty for
an sc version of amivantamab?

]]>https://dev.proinvestor.com/forum/post/7675415https://dev.proinvestor.com/forum/post/7675415Fri, 31 May 2024 13:04:29 GMTASCO LBA out: Subcutaneous amivantamab vs intravenous amivantamab https://meetings.asco.org/abstracts-presentations/232405 . seems like a slam dunk.

]]>https://dev.proinvestor.com/forum/post/7675414https://dev.proinvestor.com/forum/post/7675414Fri, 31 May 2024 12:45:28 GMTcan you also ask AI what the share price will be at the end of the year, given these conclusions?

]]>https://dev.proinvestor.com/forum/post/7675416https://dev.proinvestor.com/forum/post/7675416Fri, 31 May 2024 12:44:54 GMTAlle patienter på Dara progresserjo desværre så mener det er meget relevant on Hexabody-cd38 virker hvis ikke JnJ opter ind.

]]>https://dev.proinvestor.com/forum/post/7675412https://dev.proinvestor.com/forum/post/7675412Fri, 31 May 2024 12:41:43 GMTIn summary, the combination of enhanced CDC, robust multi-faceted mechanisms of action, effectiveness in lower CD38 expression levels, and promising preclinical results all suggest that Hexabody-CD38 should help patients who are resistant to Darzalex. The ongoing clinical trials will provide further validation of its safety and efficacy in this patient population.

]]>https://dev.proinvestor.com/forum/post/7675429https://dev.proinvestor.com/forum/post/7675429Fri, 31 May 2024 12:38:34 GMTRelief of Immune Suppression: Hexabody-CD38 strongly inhibits CD38 cyclase activity, which is hypothesized to relieve immune suppression in the tumor microenvironment, providing an additional therapeutic benefit.

]]>https://dev.proinvestor.com/forum/post/7675411https://dev.proinvestor.com/forum/post/7675411Fri, 31 May 2024 12:38:20 GMTIn Vivo and Ex Vivo Efficacy: Hexabody-CD38 has demonstrated strong anti-tumor activity in patient-derived xenograft (PDX) models and primary MM cells, including those from DARA-refractory patients, indicating its potential effectiveness in a clinical setting.

]]>https://dev.proinvestor.com/forum/post/7675410https://dev.proinvestor.com/forum/post/7675410Fri, 31 May 2024 12:38:10 GMTNo Inhibition by Preincubation with DARA: Preclinical studies indicate that preincubation with DARA does not inhibit Hexabody-CD38 from reaching its full capacity to induce CDC, suggesting that Hexabody-CD38 can still be effective even if DARA has been used previously.

]]>https://dev.proinvestor.com/forum/post/7675413https://dev.proinvestor.com/forum/post/7675413Fri, 31 May 2024 12:37:58 GMTEffective in Lower CD38 Expression: The study shows that Hexabody-CD38 is effective even in cell lines with lower levels of CD38 expression, which is a common issue in DARA-resistant multiple myeloma (MM) patients.

]]>https://dev.proinvestor.com/forum/post/7675409https://dev.proinvestor.com/forum/post/7675409Fri, 31 May 2024 12:37:45 GMT